Pliant Therapeutics Investor Relations Material
Latest events
Study Update
Pliant Therapeutics
Q1 2025
8 May, 2025
Q4 2024
3 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Pliant Therapeutics Inc
Access all reports
Pliant Therapeutics, Inc. (PTI) is a clinical stage biopharmaceutical company developing DNA-based therapeutics that enable patients to reverse fibrosis and related diseases. The company's lead product candidate, PRTX-100, is a proprietary plasmid DNA therapeutic that has completed Phase 2 testing in nonalcoholic steatohepatitis (NASH). PTI owns the rights to exclusive plasmid-based therapies optimized for solid tumors including breast and pancreatic cancers. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Key slides for Pliant Therapeutics Inc
43rd Annual J.P. Morgan Healthcare Conference 2025
Pliant Therapeutics Inc
43rd Annual J.P. Morgan Healthcare Conference 2025
Pliant Therapeutics Inc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
PLRX
Country
🇺🇸 United States